← Leaderboards
Myron Max Levine
University Of Maryland Baltimore
$22,681,817
Attributed
$22,681,817
Total exposure
14
Grants
11
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $11.5M · FY2005–23$20M$15M$10M$5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$152,077,399 · 17
By mechanism
U54$100,805,838 · 8
U19$41,000,331 · 4
R01$5,522,456 · 2
T32$3,752,356 · 1
D43$996,418 · 1
N01$0 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Maryland Baltimore
Same institution · by research overlap
- Harry L. Mobley$24,735,775
- David Serre$13,109,756
- Raphael Simon$3,358,086
- Sharon Mei Tennant$7,247,272
Others in their field
Top investigators on “Vaccines”
- Lawrence Corey · Fred Hutchinson Cancer Center$829,044,908
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$556,540,832
- Bambra Strokes · Ppd Development Lp$526,656,217
- Barton F Haynes · Duke University$515,215,260
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$398,445,678
- Dennis R. Burton · Scripps Research Institute$316,106,418
Research focus
VaccinesSalmonella TyphiBiodefenseResearch PersonnelResearch Project GrantsTranslational ResearchPreventImmune ResponseAttenuatedPathogenVaccine DevelopmentVector VaccineAreaEngineeringInstitutionPhase I Clinical TrialsSalmonellaAntibodiesOralSalmonella ParatyphiVaccinationCollaborationsAntigensAntibiotic Resistance
Grant awards (94)
Active Vaccination and Passive Antibody Strategies to Prevent Disease Caused by Multidrug-Resistant Bacterial Pathogens$2,500,000
U19 · FY2023 · AI · contact PI
Administrative Core$211,127
U19 · FY2023 · AI · contact PI
Active Vaccination and Passive Antibody Strategies to Prevent Disease Caused by Multidrug-Resistant Bacterial Pathogens$2,500,000
U19 · FY2022 · AI · contact PI
Administrative Core$320,043
U19 · FY2022 · AI · contact PI
Active Vaccination and Passive Antibody Strategies to Prevent Disease Caused by Multidrug-Resistant Bacterial Pathogens$2,500,000
U19 · FY2021 · AI · contact PI
Administrative Core$223,288
U19 · FY2021 · AI · contact PI
Active Vaccination and Passive Antibody Strategies to Prevent Disease Caused by Multidrug-Resistant Bacterial Pathogens$2,500,000
U19 · FY2020 · AI · contact PI
Administrative Core$228,714
U19 · FY2020 · AI · contact PI
Active Vaccination and Passive Antibody Strategies to Prevent Disease Caused by Multidrug-Resistant Bacterial Pathogens$2,500,000
U19 · FY2019 · AI · contact PI
Administrative Core$210,354
U19 · FY2019 · AI · contact PI
Immunoprophylactic Strategies to Control Emerging Enteric Infections$4,973,548
U19 · FY2018 · AI · contact PI
Administrative Core$339,114
U19 · FY2018 · AI · contact PI
Immunoprophylactic Strategies to Control Emerging Enteric Infections$5,312,643
U19 · FY2017 · AI · contact PI
Administrative Core$560,364
U19 · FY2017 · AI · contact PI
Fellowship Training Program in Vaccinology$143,838
T32 · FY2017 · AI · contact PI
Fellowship Training Program in Vaccinology$1,088
T32 · FY2017 · AI · contact PI
Immunoprophylactic Strategies to Control Emerging Enteric Infections$5,313,722
U19 · FY2016 · AI · contact PI
Administrative Core$496,998
U19 · FY2016 · AI · contact PI
Fellowship Training Program in Vaccinology$167,434
T32 · FY2016 · AI · contact PI
Immunoprophylactic Strategies to Control Emerging Enteric Infections$4,950,326
U19 · FY2015 · AI · contact PI
Administrative Core$233,994
U19 · FY2015 · AI · contact PI
Fellowship Training Program in Vaccinology$221,646
T32 · FY2015 · AI · contact PI
Immunoprophylactic Strategies to Control Emerging Enteric Infections$4,894,397
U19 · FY2014 · AI · contact PI
Administrative Core$231,699
U19 · FY2014 · AI · contact PI
Fellowship Training Program in Vaccinology$221,646
T32 · FY2014 · AI · contact PI
Middle Atlantic Regional Center for Excellence for Biodefense and Emerging Infect$6,823,026
U54 · FY2013 · AI · contact PI
Administrative Core$651,707
U54 · FY2013 · AI · contact PI
University of Maryland Development Research Program$502,220
U54 · FY2013 · AI · contact PI
Fellowship Training Program in Vaccinology$217,337
T32 · FY2013 · AI · contact PI
Vaccine strategy for broad spectrum protection agains non-typhoidal salmonell$202,018
U54 · FY2013 · AI · contact PI
Phase I trial of two candidate live oral salmonella enterica serovar paratyphi A$103,189
U54 · FY2013 · AI · contact PI
Middle Atlantic Regional Center for Excellence for Biodefense and Emerging Infect$8,196,905
U54 · FY2012 · AI · contact PI
Administrative Core$710,063
U54 · FY2012 · AI · contact PI
University of Maryland Development Research Program$606,523
U54 · FY2012 · AI · contact PI
Phase I trial of two candidate live oral salmonella enterica serovar paratyphi A$572,071
U54 · FY2012 · AI · contact PI
Vaccine strategy for broad spectrum protection agains non-typhoidal salmonell$231,789
U54 · FY2012 · AI · contact PI
Middle Atlantic Regional Center for Excellence for Biodefense and Emerging Infect$8,281,586
U54 · FY2011 · AI · contact PI
Administrative Core$689,407
U54 · FY2011 · AI · contact PI
University of Maryland Development Research Program$400,000
U54 · FY2011 · AI · contact PI
Vaccine strategy for broad spectrum protection agains non-typhoidal salmonell$249,990
U54 · FY2011 · AI · contact PI
Fellowship Training Program in Vaccinology$247,809
T32 · FY2011 · AI · contact PI
Phase I trial of two candidate live oral salmonella enterica serovar paratyphi A$122,838
U54 · FY2011 · AI · contact PI
Middle Atlantic Regional Center for Excellence for Biodefense and Emerging Infect$9,047,135
U54 · FY2010 · AI · contact PI
Phase I trial of two candidate live oral salmonella enterica serovar paratyphi A$793,003
U54 · FY2010 · AI · contact PI
Administrative Core$634,239
U54 · FY2010 · AI · contact PI
University of Maryland Development Research Program$438,225
U54 · FY2010 · AI · contact PI
Vaccine strategy for broad spectrum protection agains non-typhoidal salmonell$257,585
U54 · FY2010 · AI · contact PI
Fellowship Training Program in Vaccinology$183,121
T32 · FY2010 · AI · contact PI
Middle Atlantic Regional Center for Excellence for Biodefense and Emerging Infect$8,866,773
U54 · FY2009 · AI · contact PI
Middle Atlantic Regional Center for Excellence for Biodefense and Emerging Infect$669,831
U54 · FY2009 · AI · contact PI
Administrative Core$612,778
U54 · FY2009 · AI · contact PI
University of Maryland Development Research Program$422,517
U54 · FY2009 · AI · contact PI
Phase I trial of two candidate live oral salmonella enterica serovar paratyphi A$388,715
U54 · FY2009 · AI · contact PI
Fellowship Training Program in Vaccinology$252,138
T32 · FY2009 · AI · contact PI
Vaccine strategy for broad spectrum protection agains non-typhoidal salmonell$247,239
U54 · FY2009 · AI · contact PI
Defense against Biowarfare and Emerging Infection Agents$9,038,291
U54 · FY2008 · AI · contact PI
Recombinant & live oral Salmonella typhi hybrid vaccines$619,162
R01 · FY2008 · AI · contact PI
Administrative Core$348,615
U54 · FY2008 · AI · contact PI
Fellowship Training Program in Vaccinology$250,090
T32 · FY2008 · AI · contact PI
New Opportunities - Heterologous Prime-boost Product Development Project$170,161
U54 · FY2008 · AI · contact PI
Defense against Biowarfare and Emerging Infection Agents$49,982
U54 · FY2008 · AI · contact PI
Defense against Biowarfare and Emerging Infection Agents$8,974,451
U54 · FY2007 · AI · contact PI
Recombinant & live oral Salmonella typhi hybrid vaccines$469,790
R01 · FY2007 · AI · contact PI
Fellowship Training Program in Vaccinology$250,090
T32 · FY2007 · AI · contact PI
Defense against Biowarfare and Emerging Infection Agents$50,000
U54 · FY2007 · AI · contact PI
Defense against Biowarfare and Emerging Infection Agents$9,378,104
U54 · FY2006 · AI · contact PI
Recombinant & live oral Salmonella typhi hybrid vaccines$471,642
R01 · FY2006 · AI · contact PI
Fellowship training program in vaccinology$238,975
T32 · FY2006 · AI · contact PI
Defense against Biowarfare and Emerging Infection Agents$8,963,750
U54 · FY2005 · AI
Recombinant &live oral Salmonella typhi hybrid vaccines$470,885
R01 · FY2005 · AI
Fellowship training program in vaccinology$238,777
T32 · FY2005 · AI
Defense against Biowarfare and Emerging Infection Agents$9,124,674
U54 · FY2004 · AI
Recombinant &live oral Salmonella typhi hybrid vaccines$470,253
R01 · FY2004 · AI
BACTERIAL LIVE VECTOR-BASED VACCINE AGAINST MALARIA$371,250
R01 · FY2004 · AI
Fellowship training program in vaccinology$238,582
T32 · FY2004 · AI
Defense against Biowarfare and Emerging Infection Agents$3,986,438
U54 · FY2003 · AI
BACTERIAL LIVE VECTOR-BASED VACCINE AGAINST MALARIA$371,250
R01 · FY2003 · AI
Fellowship training program in vaccinology$235,234
T32 · FY2003 · AI
RECOMBINANT &LIVE ORAL SALMONELLA TYPHI HYBRID VACCINES$406,057
R01 · FY2002 · AI
BACTERIAL LIVE VECTOR-BASED VACCINE AGAINST MALARIA$352,688
R01 · FY2002 · AI
Fellowship training program in vaccinology$209,254
T32 · FY2002 · AI
INTERNATIONAL TRAINING AND RESEARCH IN EMERGING INFECTIO$175,000
D43 · FY2002 · TW
RECOMBINANT &LIVE ORAL SALMONELLA TYPHI HYBRID VACCINES$394,231
R01 · FY2001 · AI
BACTERIAL LIVE VECTOR-BASED VACCINE AGAINST MALARIA$371,250
R01 · FY2001 · AI
INTERNATIONAL TRAINING AND RESEARCH IN EMERGING INFECTIO$347,063
D43 · FY2001 · TW
FELLOWSHIP TRAINING PROGRAM IN VACCINOLOGY$224,256
T32 · FY2001 · AI
INTERNATIONAL TRAINING AND RESEARCH IN EMERGING INFECTIO$11,664
D43 · FY2001 · TW
RECOMBINANT &LIVE ORAL SALMONELLA TYPHI HYBRID VACCINES$382,748
R01 · FY2000 · AI
BACTERIAL LIVE VECTOR-BASED VACCINE AGAINST MALARIA$371,250
R01 · FY2000 · AI
INTERNATIONAL TRAINING AND RESEARCH IN EMERGING INFECTIO$246,484
D43 · FY2000 · TW
FELLOWSHIP TRAINING PROGRAM IN VACCINOLOGY$211,041
T32 · FY2000 · AI
NOMA IN CHILDREN IN DEPRIVED COMMUNITIES$136,207
D43 · FY2000 · TW
Training &Research in Mali$80,000
D43 · FY2000 · TW
CONTROL MESURES IN AGING AND INFECTIOUS DISEASE$0
N01 · FY2000 · AI